Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.69 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCND2 | P30279 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20564955 | 0.85 | CDK4 (0.57) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL29575809 | 0.83 | BRAF (0.65) | BRAFCDK4CCND1CCND2CCND3 | |
| SCHEMBL3426624 | 0.81 | BRAF (0.60) | BRAF | |
| SCHEMBL3039406 | 0.81 | BRAF (0.72) | BRAFRAF1 | |
| SCHEMBL5490360 | 0.79 | BRAF (0.64) | BRAF | |
| SCHEMBL5495483 | 0.77 | BRAF (0.43) | BRAFRAF1 | |
| SCHEMBL12671175 | 0.77 | BRAF (0.49) | BRAFRAF1 | |
| SCHEMBL17529301 | 0.77 | BRAF (0.49) | BRAF | |
| SCHEMBL5495505 | 0.76 | ADRB2 (0.58) | BRAFCDK4CCND1 | |
| SCHEMBL12120858 | 0.76 | BRAF (0.53) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA (SE) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216791-A1 | PYRIDINYLQUINAZOLINAMINE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | BRAF 1/4885CDK4 313/4885CCND1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.